Search
Results: 3
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol
Stephan Ursprung, Helen Mossop, Ferdia A. Gallagher, Evis Sala, Richard Skells, Jamal A. N. Sipple, Thomas J. Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G. Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Y. Warren, John Stone, Tim Eisen, James Wason, Sarah J. Welsh, Grant D. Stewart
Nov 22, 2021
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Stephan Ursprung, Helen Mossop, Ferdia A Gallagher, Evis Sala, Richard Skells, Jamal AN Sipple, Thomas J Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Y Warren, John Stone, Tim Eisen, James Wason, Sarah J Welsh, Grant D Stewart
Jan 07, 2022
BACKGROUND: Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments...
Bayesian adaptive trial Cediranib [MeSH] Clear cell renal cell carcinoma [MeSH] Clinical trial protocol [MeSH] Durvalumab [MeSH] Neoadjuvant therapy [MeSH] Olaparib [MeSH] Phase II clinical trial [MeSH] Window-of-opportunity Antibodies Monoclonal Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Bayes Theorem Biopsy Capillary Permeability Carcinoma Renal Cell Humans Kidney Kidney Neoplasms Lymphocytes Tumor-Infiltrating Magnetic Resonance Imaging Medical Futility Nephrectomy Non-Randomized Controlled Trials as Topic Phthalazines Piperazines Proof of Concept Study Quinazolines Treatment Outcome Tumor Burden
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Stephan Ursprung, Helen Mossop, Ferdia Gallagher, Evis Sala, Richard Skells, Jamal AN Sipple, Thomas J Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Warren, John Stone, Tim Eisen, James Wason, Sarah Welsh, Grant Stewart
Nov 05, 2021
BACKGROUND: Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments...